Screener
Prime Medicine PRME EBITDA
EBITDA at other companies
Other financials
Where this comes from
Calculated from Prime Medicine’s reported figures.
The source filing: Prime Medicine’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 8:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-053883
FAQ
- What is Prime Medicine's EBITDA?
- Prime Medicine (PRME) reported EBITDA of -$41.5M in Q2 2026.
- How has Prime Medicine's EBITDA changed year-over-year?
- Prime Medicine's EBITDA increased by 19.4% year-over-year, from -$51.51M to -$41.5M.
- What is the long-term trend for Prime Medicine's EBITDA?
- Over 3 years (2022 to 2025), Prime Medicine's EBITDA has grown at a 20.7% compound annual growth rate (CAGR), from -$114.32M to -$201.03M.
- What does EBITDA mean?
- Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.
Ask your AI about Prime Medicine's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude